Previous 10 | Next 10 |
2023-07-27 08:38:28 ET Carmell Therapeutics ( NASDAQ: CTCX ) +54% . Lipocine ( LPCN ) +36% meets primary endpoint in Patients with cirrhosis. Celestica ( CLS ) +30% Q2 earnings call release Ultralife Corporation ( ULBI ) +30% Q...
2023-07-07 17:29:48 ET Gainers: Black Diamond Therapeutics ( NASDAQ: BDTX ) +9% . CareMax ( CMAX ) +5% . Outbrain ( OB ) +5% . Sientra ( SIEN ) +4% . iHeartMedia ( IHRT ) +4% . Losers: CRISPR Therapeutics ( CR...
CAMBRIDGE, Mass and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced the...
2023-06-29 17:48:00 ET Shares of Black Diamond Therapeutics (NASDAQ: BDTX) were up 174.7% for the week as of Thursday's market close after climbing as much as 213.7%, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech company's stoc...
2023-06-29 08:47:24 ET BioXcel Therapeutics ( BTAI ) -67% . announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer’s disease-related agitation . CorMedix ( CRMD ) -21% on pricing $40M securities off...
2023-06-29 06:09:43 ET Stock index futures were little changed Thursday after some hawkish central bank comments the previous day and as the banking sector rose after passing the Federal Reserve’s annual stress test. All 23 banks met minimum capital re...
2023-06-28 18:51:03 ET Summary Positive results were released from a phase 1 study using BDTX-1535 for the treatment of EGFR non-small cell lung cancer patients; 5 out of 12 had achieved radiographic confirmed partial response. Company to meet with FDA in Q4 of 2023 to see if it c...
2023-06-28 16:51:23 ET Black Diamond Therapeutics ( NASDAQ: BDTX ) has planned a public offering of its common stock to raise $75 million, the company said Wednesday. The underwriters will have a 30-day option to purchase up to an additional $11.25 million in shares. ...
CAMBRIDGE, Mass. and NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced th...
2023-06-27 13:42:36 ET Today we are diving into the world of penny stocks. This sector has a notorious reputation in the market, and rightfully so – it can be volatile and risky. However, with the right approach, a level head, and disciplined strategies, penny stocks can offer so...
News, Short Squeeze, Breakout and More Instantly...
Black Diamond Therapeutics Inc. Company Name:
BDTX Stock Symbol:
NASDAQ Market:
Black Diamond Therapeutics Inc. Website:
2024-07-31 09:00:12 ET Laura Prendergast from Raymond James issued a price target of $20.00 for BDTX on 2024-07-31 08:18:00. The adjusted price target was set to $20.00. At the time of the announcement, BDTX was trading at $5.91. The overall price target consensus is at ...
2024-06-17 20:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment Initial data from Phase 0/1 “trigger” (“window of opportunity”) inves...